{"id":7289,"date":"2025-06-20T22:05:00","date_gmt":"2025-06-20T16:35:00","guid":{"rendered":"https:\/\/chiralpedia.com\/blog\/?p=7289"},"modified":"2025-06-21T08:17:59","modified_gmt":"2025-06-21T02:47:59","slug":"episode-10-future-reflections-how-the-story-of-chiral-drug-regulation-continues","status":"publish","type":"post","link":"https:\/\/chiralpedia.com\/blog\/episode-10-future-reflections-how-the-story-of-chiral-drug-regulation-continues\/","title":{"rendered":"Episode 10: Future Reflections: How the Story of Chiral Drug Regulation Continues"},"content":{"rendered":"\n<p class=\"has-vivid-red-color has-text-color has-link-color wp-elements-8977109feb1d06fdb74fb3402165b257\"><em><strong>&#8220;Approval is not the end of a molecule\u2019s journey &#8211; the mirror must be watched, studied, and questioned throughout its life.&#8221;<\/strong><\/em><\/p>\n\n\n\n<p class=\"has-ast-global-color-0-color has-text-color has-link-color has-medium-font-size wp-elements-81c47aea2e5cee11d71e578c65a2be9b\"><strong>Introduction<\/strong><\/p>\n\n\n\n<p>The development and approval of chiral drugs, especially single-enantiomer entities, marked a new chapter in pharmaceutical science. However, <strong>approval is only the beginning<\/strong>. Ensuring that a chiral drug continues to behave safely and predictably in the real world demands <strong>vigilant post-marketing surveillance<\/strong>, <strong>adaptive regulatory frameworks<\/strong>, and <strong>constant scientific reevaluation<\/strong>.<\/p>\n\n\n\n<p>In this final episode, we explore the <strong>lifecycle management<\/strong> of chiral drugs post-approval:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>How do pharmacovigilance systems monitor chiral-specific safety issues?<\/li>\n\n\n\n<li>What regulatory mechanisms exist to detect late-emerging risks?<\/li>\n\n\n\n<li>How might future chiral drug development evolve toward better transparency, efficiency, and personalization?<\/li>\n<\/ul>\n\n\n\n<figure class=\"wp-block-image aligncenter size-full is-resized\"><img loading=\"lazy\" decoding=\"async\" width=\"612\" height=\"750\" src=\"https:\/\/chiralpedia.com\/blog\/wp-content\/uploads\/2025\/04\/E-10-01-visual-selection.png\" alt=\"\" class=\"wp-image-7771\" style=\"width:570px;height:auto\" srcset=\"https:\/\/chiralpedia.com\/blog\/wp-content\/uploads\/2025\/04\/E-10-01-visual-selection.png 612w, https:\/\/chiralpedia.com\/blog\/wp-content\/uploads\/2025\/04\/E-10-01-visual-selection-245x300.png 245w\" sizes=\"auto, (max-width: 612px) 100vw, 612px\" \/><\/figure>\n\n\n\n<p>The mirror image metaphor reminds us: molecules that once seemed well understood can reveal hidden faces over time.<\/p>\n\n\n\n<p class=\"has-ast-global-color-0-color has-text-color has-link-color has-medium-font-size wp-elements-d1bca00a5d1b8be3140b1d649d167789\"><strong>Post-Marketing Pharmacovigilance for Chiral Drugs<\/strong><\/p>\n\n\n\n<p><strong>Pharmacovigilance<\/strong> refers to the science and activities relating to the detection, assessment, understanding, and prevention of adverse effects or any other drug-related problems.<\/p>\n\n\n\n<p>For chiral drugs, specific considerations include:<\/p>\n\n\n\n<p><strong>1. Enantiomer-Specific Adverse Events<\/strong><\/p>\n\n\n\n<p>While both enantiomers are usually studied during development, rare or subtle enantiomer-specific adverse events may not emerge until <strong>large-scale post-marketing exposure<\/strong>.<\/p>\n\n\n\n<p>Examples:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>If the distomer is minimally active but bioaccumulates over time, delayed toxicity could occur.<\/li>\n\n\n\n<li>If stereoselective metabolism shifts in certain populations (e.g., genetic polymorphisms), one enantiomer could unexpectedly dominate, altering therapeutic outcomes.<\/li>\n<\/ul>\n\n\n\n<p>Thus, pharmacovigilance must remain <strong>enantiomer-aware<\/strong> (EMA, 2005).<\/p>\n\n\n\n<figure class=\"wp-block-image aligncenter size-full is-resized\"><img loading=\"lazy\" decoding=\"async\" width=\"661\" height=\"526\" src=\"https:\/\/chiralpedia.com\/blog\/wp-content\/uploads\/2025\/04\/E10-01-visual-selection.png\" alt=\"\" class=\"wp-image-7773\" style=\"width:507px;height:auto\" srcset=\"https:\/\/chiralpedia.com\/blog\/wp-content\/uploads\/2025\/04\/E10-01-visual-selection.png 661w, https:\/\/chiralpedia.com\/blog\/wp-content\/uploads\/2025\/04\/E10-01-visual-selection-300x239.png 300w\" sizes=\"auto, (max-width: 661px) 100vw, 661px\" \/><\/figure>\n\n\n\n<p><strong>2. Monitoring for Chiral Instability<\/strong><\/p>\n\n\n\n<p>Dynamic racemization or atropisomerization may lead to:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Loss of therapeutic potency.<\/li>\n\n\n\n<li>Formation of untested stereoisomers.<\/li>\n\n\n\n<li>Unexpected side effects.<\/li>\n<\/ul>\n\n\n\n<p>Stability-indicating assays must be incorporated into:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Ongoing stability studies.<\/li>\n\n\n\n<li>Pharmacovigilance investigations when product complaints arise.<\/li>\n<\/ul>\n\n\n\n<p>Regulators expect manufacturers to <strong>update quality documentation<\/strong> if significant instability is detected post-approval (ICH, 2003).<\/p>\n\n\n\n<figure class=\"wp-block-image aligncenter size-full is-resized\"><img loading=\"lazy\" decoding=\"async\" width=\"854\" height=\"996\" src=\"https:\/\/chiralpedia.com\/blog\/wp-content\/uploads\/2025\/04\/E10-02-visual-selection.png\" alt=\"\" class=\"wp-image-7774\" style=\"width:564px;height:auto\" srcset=\"https:\/\/chiralpedia.com\/blog\/wp-content\/uploads\/2025\/04\/E10-02-visual-selection.png 854w, https:\/\/chiralpedia.com\/blog\/wp-content\/uploads\/2025\/04\/E10-02-visual-selection-257x300.png 257w, https:\/\/chiralpedia.com\/blog\/wp-content\/uploads\/2025\/04\/E10-02-visual-selection-768x896.png 768w\" sizes=\"auto, (max-width: 854px) 100vw, 854px\" \/><\/figure>\n\n\n\n<p><strong>3. Real-World Evidence (RWE) and Chiral Drugs<\/strong><\/p>\n\n\n\n<p>RWE -data collected from routine clinical practice -offers powerful tools for:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Detecting stereochemistry-dependent efficacy issues.<\/li>\n\n\n\n<li>Studying long-term safety across diverse populations.<\/li>\n\n\n\n<li>Informing potential label updates regarding enantiomer-specific risks.<\/li>\n<\/ul>\n\n\n\n<p>As databases grow, enantiomer-specific pharmacovigilance will become more sophisticated, combining <strong>big data analytics<\/strong> with traditional post-marketing reporting (FDA, 2018).<\/p>\n\n\n\n<figure class=\"wp-block-image aligncenter size-full is-resized\"><img loading=\"lazy\" decoding=\"async\" width=\"765\" height=\"588\" src=\"https:\/\/chiralpedia.com\/blog\/wp-content\/uploads\/2025\/04\/E10-03-visual-selection.png\" alt=\"\" class=\"wp-image-7775\" style=\"width:537px;height:auto\" srcset=\"https:\/\/chiralpedia.com\/blog\/wp-content\/uploads\/2025\/04\/E10-03-visual-selection.png 765w, https:\/\/chiralpedia.com\/blog\/wp-content\/uploads\/2025\/04\/E10-03-visual-selection-300x231.png 300w\" sizes=\"auto, (max-width: 765px) 100vw, 765px\" \/><\/figure>\n\n\n\n<p class=\"has-ast-global-color-0-color has-text-color has-link-color has-medium-font-size wp-elements-fddfc110cf2ad0765c0ed9b03415f83a\"><strong>Lifecycle Management of Chiral Drugs<\/strong><\/p>\n\n\n\n<p>Beyond initial approval, maintaining the safety and efficacy of chiral drugs requires proactive lifecycle strategies:<\/p>\n\n\n\n<p><strong>1. Continuous Stability Monitoring<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Long-term real-time stability studies must explicitly assess chiral integrity.<\/li>\n\n\n\n<li>New stress conditions (e.g., new storage temperatures) may reveal hidden vulnerabilities.<\/li>\n<\/ul>\n\n\n\n<p><strong>2. Updating Specifications and Controls<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>If enantiomeric ratios shift over time, release specifications may need tightening.<\/li>\n\n\n\n<li>Pharmacopoeial monographs for chiral drugs often evolve to incorporate improved methods for enantiomeric purity testing.<\/li>\n<\/ul>\n\n\n\n<p><strong>3. Risk Management Plans (RMPs) for Chiral-Specific Risks<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Modern approvals often include RMPs focused on chiral aspects:\n<ul class=\"wp-block-list\">\n<li>Monitoring for signs of unexpected enantiomer accumulation.<\/li>\n\n\n\n<li>Special populations (e.g., liver disease patients with impaired stereoselective metabolism).<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n\n\n\n<p>These RMPs align with ICH E2E guidance on pharmacovigilance planning (ICH, 2005).<\/p>\n\n\n\n<figure class=\"wp-block-image aligncenter size-full is-resized\"><img loading=\"lazy\" decoding=\"async\" width=\"1008\" height=\"504\" src=\"https:\/\/chiralpedia.com\/blog\/wp-content\/uploads\/2025\/04\/E10-04-visual-selection.png\" alt=\"\" class=\"wp-image-7776\" style=\"width:618px;height:auto\" srcset=\"https:\/\/chiralpedia.com\/blog\/wp-content\/uploads\/2025\/04\/E10-04-visual-selection.png 1008w, https:\/\/chiralpedia.com\/blog\/wp-content\/uploads\/2025\/04\/E10-04-visual-selection-300x150.png 300w, https:\/\/chiralpedia.com\/blog\/wp-content\/uploads\/2025\/04\/E10-04-visual-selection-768x384.png 768w\" sizes=\"auto, (max-width: 1008px) 100vw, 1008px\" \/><\/figure>\n\n\n\n<p class=\"has-ast-global-color-0-color has-text-color has-link-color has-medium-font-size wp-elements-422c4dcf701d9d1aeaa4a01193f11f34\"><strong>Learning from the Past: Case Studies in Chiral Pharmacovigilance<\/strong><\/p>\n\n\n\n<p class=\"has-vivid-red-color has-text-color has-link-color wp-elements-d291d6078d11994672d913a362ea38e4\"><strong>Thalidomide: A Perpetual Warning<\/strong><\/p>\n\n\n\n<p>The tragic lessons of thalidomide remind us that even subtle stereochemical changes -here, in vivo racemization -can have catastrophic consequences if ignored post-approval (McBride, 1961).<\/p>\n\n\n\n<p class=\"has-vivid-red-color has-text-color has-link-color wp-elements-a91f3bd9f122f5ed04dee2c18add181f\"><strong>Esomeprazole: Successful Lifecycle Stewardship<\/strong><\/p>\n\n\n\n<p>Post-approval monitoring confirmed the stability and consistent performance of esomeprazole across global markets, reinforcing its therapeutic positioning (Andersson, 2001).<\/p>\n\n\n\n<p class=\"has-ast-global-color-0-color has-text-color has-link-color has-medium-font-size wp-elements-5cd0425fafd208175365c6452a774647\"><strong>The Future: Innovations in Chiral Pharmacovigilance<\/strong><\/p>\n\n\n\n<p>Several scientific advances promise to strengthen the post-marketing safety of chiral drugs:<\/p>\n\n\n\n<p><strong>1. Chiral-Specific Biomarkers<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Identifying biomarkers sensitive to enantiomeric imbalance could allow early detection of stereochemistry-dependent adverse effects.<\/li>\n<\/ul>\n\n\n\n<p><strong>2. AI and Machine Learning<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Predictive models could analyze post-marketing data for patterns suggesting stereoselective toxicity or loss of efficacy.<\/li>\n\n\n\n<li>AI could assist in automating detection of chiral-specific safety signals hidden in large datasets (Rajkomar et al., 2019).<\/li>\n<\/ul>\n\n\n\n<p><strong>3. Personalized Pharmacovigilance<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Genotype-based pharmacovigilance could anticipate and manage stereoselective metabolism risks in individuals (Zhou, 2011).<\/li>\n<\/ul>\n\n\n\n<figure class=\"wp-block-image aligncenter size-full is-resized\"><img loading=\"lazy\" decoding=\"async\" width=\"828\" height=\"618\" src=\"https:\/\/chiralpedia.com\/blog\/wp-content\/uploads\/2025\/04\/E10-06-visual-selection.png\" alt=\"\" class=\"wp-image-7778\" style=\"width:590px;height:auto\" srcset=\"https:\/\/chiralpedia.com\/blog\/wp-content\/uploads\/2025\/04\/E10-06-visual-selection.png 828w, https:\/\/chiralpedia.com\/blog\/wp-content\/uploads\/2025\/04\/E10-06-visual-selection-300x224.png 300w, https:\/\/chiralpedia.com\/blog\/wp-content\/uploads\/2025\/04\/E10-06-visual-selection-768x573.png 768w\" sizes=\"auto, (max-width: 828px) 100vw, 828px\" \/><\/figure>\n\n\n\n<p class=\"has-ast-global-color-0-color has-text-color has-link-color has-medium-font-size wp-elements-6780e8b34da2a01b4fd57a6d411144d9\"><strong>Toward a Future of Ethical, Transparent, and Patient-Centric Chirality<\/strong><\/p>\n\n\n\n<p>Chiral drug development and regulation have made extraordinary progress. Yet, continued vigilance is essential:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Transparency<\/strong> about enantiomeric properties must persist across the drug lifecycle.<\/li>\n\n\n\n<li><strong>Ethical stewardship<\/strong> of chiral innovations must prioritize patient welfare over commercial imperatives.<\/li>\n\n\n\n<li><strong>Scientific curiosity<\/strong> must continue to challenge assumptions and investigate the hidden dimensions of molecular asymmetry.<\/li>\n<\/ul>\n\n\n\n<p>Ultimately, the regulatory odyssey of chiral drugs reflects broader truths about medicine:<br>What seems simple often harbors unseen complexities.<br>What we control today must be watched tomorrow.<\/p>\n\n\n\n<p class=\"has-ast-global-color-0-color has-text-color has-link-color has-medium-font-size wp-elements-9e316c1999adbcade6b8c6749c3afcd7\"><strong>Conclusion<\/strong><\/p>\n\n\n\n<p>The story of chiral drugs -from regulatory neglect to sophisticated vigilance -is a triumph of scientific learning, ethical introspection, and global collaboration. As chemistry, biology, and data science converge, the future promises even more precise, safer, and patient-centered applications of chirality. But no matter how advanced our technologies or comprehensive our regulations become, <strong>the mirror image principle remains<\/strong>: The true nature of things often reveals itself only when viewed from all sides -patiently, humbly, and continuously.<\/p>\n\n\n\n<p class=\"has-vivid-red-color has-text-color has-link-color has-medium-font-size wp-elements-d0ff9fdc5fc4f85e2ccb423df362d987\"><strong>\ud83d\udcd6 Series Summary and Final Reflection<\/strong><\/p>\n\n\n\n<p>Over these ten episodes, we have traced the extraordinary evolution of chiral drug regulation:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>From the ignorance of stereochemistry before the 1990s.<\/li>\n\n\n\n<li>Through the transformative regulatory shifts of the 1990s.<\/li>\n\n\n\n<li>Across global agency differences, technological revolutions, scientific debates, and ethical-economic dilemmas.<\/li>\n\n\n\n<li>Into the emerging challenges of complex chirality and the unending need for vigilance.<\/li>\n<\/ul>\n\n\n\n<p>The regulatory odyssey of chiral drugs mirrors our own: a journey from simplicity to complexity, from confidence to humility, from isolated insights to holistic understanding. The story -like the molecules themselves -continues.<\/p>\n\n\n\n<figure class=\"wp-block-image aligncenter size-large is-resized\"><img loading=\"lazy\" decoding=\"async\" width=\"1024\" height=\"1004\" src=\"https:\/\/chiralpedia.com\/blog\/wp-content\/uploads\/2025\/04\/E10-S-visual-selection-1024x1004.png\" alt=\"\" class=\"wp-image-7781\" style=\"width:574px;height:auto\" srcset=\"https:\/\/chiralpedia.com\/blog\/wp-content\/uploads\/2025\/04\/E10-S-visual-selection-1024x1004.png 1024w, https:\/\/chiralpedia.com\/blog\/wp-content\/uploads\/2025\/04\/E10-S-visual-selection-300x294.png 300w, https:\/\/chiralpedia.com\/blog\/wp-content\/uploads\/2025\/04\/E10-S-visual-selection-768x753.png 768w, https:\/\/chiralpedia.com\/blog\/wp-content\/uploads\/2025\/04\/E10-S-visual-selection.png 1044w\" sizes=\"auto, (max-width: 1024px) 100vw, 1024px\" \/><\/figure>\n\n\n\n<p class=\"has-ast-global-color-0-color has-text-color has-link-color has-medium-font-size wp-elements-7a625832489ffca6df3878dd799ad21c\"><strong>&nbsp;References<\/strong><\/p>\n\n\n\n<p>Andersson, T. (2001). Pharmacokinetics, metabolism and interactions of acid pump inhibitors: Focus on omeprazole, lansoprazole, pantoprazole, and rabeprazole. <em>Clinical Pharmacokinetics, 40<\/em>(7), 523\u2013538.<\/p>\n\n\n\n<p>European Medicines Agency (EMA). (2005). <em>Guideline on Risk Management Systems for Medicinal Products for Human Use<\/em> (EMEA\/CHMP\/96268\/2005).<\/p>\n\n\n\n<p>Food and Drug Administration (FDA). (1992). <em>Development of New Stereoisomeric Drugs<\/em> (Policy Statement). Federal Register, 57(88), 22249\u201322250.<\/p>\n\n\n\n<p>Food and Drug Administration (FDA). (2018). <em>Framework for FDA&#8217;s Real-World Evidence Program<\/em>.<\/p>\n\n\n\n<p>International Council for Harmonisation (ICH). (2003). <em>Q1E: Evaluation of Stability Data<\/em>.<\/p>\n\n\n\n<p>International Council for Harmonisation (ICH). (2005). <em>E2E: Pharmacovigilance Planning<\/em>.<\/p>\n\n\n\n<p>LaPlante, S. R., Edwards, P. J., Fader, L. D., Jakalian, A., &amp; Hucke, O. (2011). Revealing atropisomer axial chirality in drug discovery. <em>ChemMedChem, 6<\/em>(3), 505\u2013513.<\/p>\n\n\n\n<p>McBride, W. G. (1961). Thalidomide and congenital abnormalities. <em>The Lancet, 278<\/em>(7216), 1358.<\/p>\n\n\n\n<p>Rajkomar, A., Dean, J., &amp; Kohane, I. (2019). Machine learning in medicine. <em>New England Journal of Medicine, 380<\/em>(14), 1347\u20131358.<\/p>\n\n\n\n<p>Zhou, S. F. (2011). Drugs behave as substrates, inhibitors and inducers of human cytochrome P450 3A4. <em>Current Drug Metabolism, 9<\/em>(4), 310\u2013322.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>&#8220;Approval is not the end of a molecule\u2019s journey &#8211; the mirror must be watched, studied, and questioned throughout its life.&#8221; Introduction The development and approval of chiral drugs, especially single-enantiomer entities, marked a new chapter in pharmaceutical science. However, approval is only the beginning. Ensuring that a chiral drug continues to behave safely and predictably in the real world demands vigilant post-marketing surveillance, adaptive regulatory frameworks, and constant scientific reevaluation. In this final episode, &hellip;<\/p>\n<p class=\"read-more\"> <a class=\"\" href=\"https:\/\/chiralpedia.com\/blog\/episode-10-future-reflections-how-the-story-of-chiral-drug-regulation-continues\/\"> <span class=\"screen-reader-text\">Episode 10: Future Reflections: How the Story of Chiral Drug Regulation Continues<\/span> Read More &raquo;<\/a><\/p>\n","protected":false},"author":1,"featured_media":7783,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"site-sidebar-layout":"","site-content-layout":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","footnotes":""},"categories":[7,43,116],"tags":[23,22],"ppma_author":[93,95],"class_list":["post-7289","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-chiral-science","category-chirality","category-regulatory-affairs","tag-chiral_drugs","tag-chirality"],"authors":[{"term_id":93,"user_id":1,"is_guest":0,"slug":"chiralusrblg","display_name":"Valliappan Kannappan","avatar_url":{"url":"https:\/\/chiralpedia.com\/blog\/wp-content\/uploads\/2024\/09\/vk.jpg","url2x":"https:\/\/chiralpedia.com\/blog\/wp-content\/uploads\/2024\/09\/vk.jpg"},"first_name":"","last_name":"","user_url":"https:\/\/chiralpedia.com\/blog\/","job_title":"Founder, chiralpedia.com","description":""},{"term_id":95,"user_id":2,"is_guest":0,"slug":"chandramouli-r","display_name":"Chandramouli R","avatar_url":"https:\/\/secure.gravatar.com\/avatar\/dafe0b6a18e9248eb688088e3e993360328363d8d087bbd01648f0bddae05eb5?s=96&d=mm&r=g","first_name":"","last_name":"","user_url":"","job_title":"","description":""}],"_links":{"self":[{"href":"https:\/\/chiralpedia.com\/blog\/wp-json\/wp\/v2\/posts\/7289","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/chiralpedia.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/chiralpedia.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/chiralpedia.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/chiralpedia.com\/blog\/wp-json\/wp\/v2\/comments?post=7289"}],"version-history":[{"count":13,"href":"https:\/\/chiralpedia.com\/blog\/wp-json\/wp\/v2\/posts\/7289\/revisions"}],"predecessor-version":[{"id":7785,"href":"https:\/\/chiralpedia.com\/blog\/wp-json\/wp\/v2\/posts\/7289\/revisions\/7785"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/chiralpedia.com\/blog\/wp-json\/wp\/v2\/media\/7783"}],"wp:attachment":[{"href":"https:\/\/chiralpedia.com\/blog\/wp-json\/wp\/v2\/media?parent=7289"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/chiralpedia.com\/blog\/wp-json\/wp\/v2\/categories?post=7289"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/chiralpedia.com\/blog\/wp-json\/wp\/v2\/tags?post=7289"},{"taxonomy":"author","embeddable":true,"href":"https:\/\/chiralpedia.com\/blog\/wp-json\/wp\/v2\/ppma_author?post=7289"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}